⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25276596 | 0.90 | — | — | |
| SCHEMBL18964699 | 0.64 | — | — | |
| SCHEMBL787772 | 0.64 | — | — | |
| SCHEMBL16821938 | 0.57 | — | — | |
| SCHEMBL322426 | 0.57 | — | — | |
| SCHEMBL1075123 | 0.56 | — | — | |
| Hydrochloric Acid SCHEMBL28051464 | 0.55 | — | — | |
| SCHEMBL27799115 | 0.55 | — | — | |
| SCHEMBL31190154 | 0.55 | — | — | |
| SCHEMBL27867511 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | disclosed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025217430-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025029075-A1 | NOVEL BIPHENYL DERIVATIVE AS PD-L1 INHIBITOR | (주)아이랩 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025005635-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024264072-A2 | PARP INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118488953-A | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023110958-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-9336921-B2 | Electrically conducting composites, methods of manufacture thereof and articles comprising the same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9238652-B2 | Processes for the preparation of an apoptosis-inducing agent | ABBVIE INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233922-B2 | Process for producing N-(hetero)arylazoles | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20150252042-A1 | PROCESSES FOR THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150170783-A1 | ELECTRICALLY CONDUCTING COMPOSITES, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-18 | — | — | US | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140371461-A1 | PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |